June 3, 2021 11:46 AM EDTUpdated 12:10 PM
R&D

#AS­CO21: No­var­tis flash­es 'ground­break­ing data' for $2B ra­di­oli­gand drug

Jason Mast

Editor

Here’s the “ground­break­ing” da­ta from the prostate can­cer drug No­var­tis spent $2 bil­lion to ac­quire: The mol­e­cule hit every end­point in the Phase III tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times